Annovis Bio logo
Annovis Bio ANVS
$ 2.3 1.32%

Annual report 2025
added 03-13-2026

report update icon

Annovis Bio Balance Sheet 2011-2026 | ANVS

Annual Balance Sheet Annovis Bio

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - - - -8.07 M - - - - - - - - -

Total Current Liabilities

3.64 M 3.88 M 4.28 M 7.7 M 1.51 M 578 K - - - - - - - - -

Total Liabilities

4.23 M 4.62 M 18 M 7.7 M 1.51 M 578 K - - - - - - - - -

Retained Earnings

-164 M -135 M -110 M -54.1 M -28.7 M -14.2 M - - - - - - - - -

Total Assets

21.1 M 13.9 M 10.2 M 36 M 46 M 8.12 M - - - - - - - - -

Cash and Cash Equivalents

19.5 M 10.6 M 5.75 M 28.4 M 45.7 M 8.07 M 1.86 K - - - - - - - -

Book Value

16.9 M 9.31 M -7.75 M 28.3 M 44.5 M 7.54 M - - - - - - - - -

Total Shareholders Equity

16.9 M 9.31 M -7.75 M 28.3 M 44.5 M 7.54 M -8.58 M - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Annovis Bio

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Total Non Current Liabilities

- - - - - - - - - - - - - - - - - - - - - - - 606 K 606 K 606 K 606 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

4.03 M 3.12 M 2.68 M 4.62 M 7.3 M 6.8 M 11.2 M 18 M 3.56 M 2.07 M 5.41 M 7.7 M 2.53 M 1.3 M 1.4 M 1.51 M 1.12 M 884 K 1.6 M 578 K 578 K 578 K 578 K 2.62 M 2.62 M 2.62 M 2.62 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-154 M -147 M -140 M -135 M -129 M -116 M -111 M -110 M -88 M -73.3 M -63.8 M -54.1 M -46.3 M -39.9 M -34 M -28.7 M -22.8 M -20 M -17.4 M -14.2 M -14.2 M -14.2 M -14.2 M -8.78 M -8.78 M -8.78 M -8.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

17.2 M 21.5 M 26.7 M 13.9 M 14.4 M 5.05 M 7.81 M 10.2 M 10.2 M 22.8 M 25.5 M 36 M 37.1 M 40 M 44.1 M 46 M 47.7 M 49.5 M 5.96 M 8.12 M 8.12 M 8.12 M 8.12 M 1.12 M 1.12 M 1.12 M 1.12 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

15.3 M 17.1 M 22.2 M 10.6 M 12.6 M 4 M 3.14 M 5.75 M 6.35 M 15.7 M 16.8 M 28.4 M 32 M 36 M 42.7 M 45.7 M 47.5 M 49.2 M 5.6 M 8.07 M 8.07 M 8.07 M 8.07 M 1.86 K 1.86 K 1.86 K 1.86 K 35.3 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

13.2 M 18.3 M 24.1 M 9.31 M 7.06 M -1.75 M -3.35 M -7.75 M 6.66 M 20.7 M 20.1 M 28.3 M 34.6 M 38.7 M 42.7 M 44.5 M 46.5 M 48.6 M 4.37 M 7.54 M 7.54 M 7.54 M 7.54 M -1.5 M -1.5 M -1.5 M -1.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

13.2 M 18.3 M 24.1 M 9.31 M 7.06 M -1.75 M -3.35 M -7.75 M 6.66 M 20.7 M 20.1 M 28.3 M 34.6 M 38.7 M 42.7 M 44.5 M 46.5 M 48.6 M 4.37 M 7.54 M 7.54 M 7.54 M 7.54 M -8.58 M -8.58 M -8.58 M -8.58 M -7.59 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Annovis Bio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.56 2.13 % $ 3.74 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.43 3.62 % $ 368 M usaUSA
argenx SE argenx SE
ARGX
$ 785.07 2.57 % $ 25 B niderlandNiderland
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 327.25 2.42 % $ 42.9 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aytu BioScience Aytu BioScience
AYTU
$ 2.66 3.5 % $ 16.7 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.9 3.7 % $ 9.38 B australiaAustralia
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.4 -0.87 % $ 954 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.18 1.21 % $ 447 M usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.61 5.76 % $ 3.13 B usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.09 0.65 % $ 310 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 9.56 % $ 397 M britainBritain
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
- - $ 2.18 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
Forte Biosciences Forte Biosciences
FBRX
$ 26.27 0.38 % $ 340 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.88 2.11 % $ 261 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA